1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,680 | 4,960 | 18:23 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Elicio Therapeutics GAAP EPS of -$1.39 | 1 | Seeking Alpha | ||
| 14.11. | Elicio Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| 13.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 47 | GlobeNewswire (Europe) | AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival ("DFS") expected in H1 2025Poster presentation at the Society for... ► Artikel lesen | |
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11. | Elicio reports promising Phase 1 cancer vaccine trial results | 1 | Investing.com | ||
| 07.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer ("SITC") 2024 Annual Meeting | 34 | GlobeNewswire (Europe) | Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival... ► Artikel lesen | |
| 07.11. | Elicio Therapeutics adjourns annual meeting due to lack of quorum | 1 | Investing.com | ||
| 07.11. | Elicio Therapeutics vertagt Jahreshauptversammlung aufgrund fehlender Beschlussfähigkeit | - | Investing.com Deutsch | ||
| 07.11. | Elicio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.10. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit | 1 | GlobeNewswire (USA) | ||
| 30.10. | Elicio Therapeutics stock rated Buy with $9 target by Jones Trading | 1 | Investing.com | ||
| 17.10. | Elicio Therapeutics announces new CFO and accounting officer | 1 | Investing.com | ||
| 17.10. | Elicio Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 16.10. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 66 | GlobeNewswire (Europe) | BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 17.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 251 | GlobeNewswire (Europe) | BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines | 2 | GlobeNewswire (USA) | ||
| 30.08. | Elicio Therapeutics CFO resigns to pursue new opportunity | 1 | Investing.com | ||
| 30.08. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 14.08. | Elicio Therapeutics GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
| 13.08. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| NANOREPRO | 1,600 | +3,90 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| OCUGEN | 0,891 | +2,41 % | Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST | ||
| VIKING THERAPEUTICS | 50,76 | +3,76 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability | DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | 0,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,000 | +0,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Launches ORLADEYO (berotralstat) in Ireland | ||
| REDHILL BIOPHARMA | 6,370 | -6,32 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| VAXART | 0,574 | -0,61 % | Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| IBIO | 2,270 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,334 | +1,83 % | Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom... ► Artikel lesen | |
| ALDEYRA | 4,480 | -0,71 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases,... ► Artikel lesen | |
| MANNKIND | 6,692 | +2,58 % | MannKind Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) revealed a profit for its third quarter that increased from last year and beat the Street estimates.The company's earnings totaled $11.55 million... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest |
Das Unternehmen ELICIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,140 (-2,92 %) liegt der Kurs bei 4,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
